scFv(TACSTD2)-OX40-CD3zeta CAR-T Lentivirus

The scFv(TACSTD2)-OX40-CD3zeta CAR-T Lentivirus is a recombinant, replication-deficient lentiviral vector designed to redirect T cell specificity toward cells expressing Tumor-Associated Calcium Signal Transducer 2 (TACSTD2), also known as TROP2. The genetic cargo encodes a Chimeric Antigen Receptor (CAR) featuring a specific scFv sequence derived from anti-TROP2 monoclonal antibodies, fused to a transmembrane domain and a potent intracellular signaling complex. This complex integrates the OX40 (CD134) co-stimulatory signaling domain with the CD3-zeta activation domain. By utilizing a lentiviral delivery system, the construct is stably integrated into the T cell genome, ensuring long-term expression and inheritance of the CAR during T cell proliferation. This specific design aims to harness the unique co-stimulatory properties of OX40, which plays a pivotal role in enhancing the survival, expansion, and anti-tumor persistence of engineered T cells when compared to traditional co-stimulatory motifs.

In terms of practical application, this lentivirus is a vital reagent for the development and validation of adoptive cell therapies targeting TROP2-positive solid tumors, including breast, lung, and gastric carcinomas. It is primarily used to transduce primary human T cells or established T cell lines to evaluate the antigen-specific lytic activity and cytokine secretion profiles in co-culture assays with target tumor cells. The product is also instrumental in studying the metabolic reprogramming and phenotypic exhaustion of CAR-T cells, particularly how OX40 signaling modulates the balance between effector and memory subsets. In vivo, these engineered cells are frequently used in systemic or orthotopic tumor models to assess tumor clearance rates and the durability of the immune response. Furthermore, it serves as a reliable benchmark for comparing different CAR architectures or testing synergistic effects when combined with checkpoint inhibitors or other small molecule modulators in the field of cancer immunotherapy research.